Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$22.86
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
332.4
2026-04-01
M2 Money Supply
$22.8T
2026-04-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 102.5; M2 money supply is $22.8T; CPI index stands at 332.4.
SWOT Analysis — PCRX
Inflationary BoomStrengths
EPS (Diluted): $0.16 (+107.4% YoY) — Earnings per share rose 107% — each share earned more.
Net Income: $7.0M (+107.1% YoY) — Profit grew 107% — the company kept more of each dollar earned.
Revenue: $541.5M (+26.0% YoY) — Revenue grew 26% — the company sold more goods or services than the prior year.
Weaknesses
Operating Cash Flow: $152.0M (-19.7% YoY) — Operating cash flow fell 20% but remained positive.
Total Assets: $1.3B (-18.6% YoY) — Total assets shrank 19% — the balance sheet contracted.
Opportunities
No clear opportunities identified at this time.
Threats
No significant threats flagged.
Financial Charts
Revenue vs Net Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
EPS (Diluted)
$0.16
was $-2.15
Earnings per share rose 107% — each share earned more.
Net Income
$7.0M
was -$99.6M
Profit grew 107% — the company kept more of each dollar earned.
Revenue
$541.5M
was $429.6M
Revenue grew 26% — the company sold more goods or services than the prior year.
Operating Cash Flow
$152.0M
was $189.4M
Operating cash flow fell 20% but remained positive.
Total Assets
$1.3B
was $1.6B
Total assets shrank 19% — the balance sheet contracted.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PCRX
Links open broker research pages. Not an endorsement or recommendation.
Research PACIRA BIOSCIENCES, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.